Pronounced Regional Variation in Esketamine and Ketamine Prescribing to US Medicaid Patients
Alexia G. Aguilar, Burke A. Beauregard, Christopher P. Conroy, Yashoda T. Khatiwoda, Shantia M. E. Horsford, Stephanie D. Nichols, Brian J. Piper
medRxiv Preprint Server April 23, 2022 preprint DOI: 10.1101/2022.04.23.22274206 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Interventions | Ketamine Esketamine |
| Topics | Depression Esketamine Ketamine |
| Keywords | Depression treatment Rapid-acting treatments Mental health interventions Healthcare disparities Geographic disparities Regional variations Unequal access Access to care Medicaid data Medicaid patients Patient data analysis Public health insurance Pharmaceutical access Drug prescribing Medication access Treatment availability |
| Citations | 2 |
| Key findings | Ketamine and esketamine are efficacious for treatment-resistant depression, lack a therapeutic delay, and do not increase risk for suicidal thoughts and behaviors in adolescents and young adults. |
Abstract
Background Ketamine and esketamine are efficacious for treatment resistant depression. Unlike other antidepressants, ketamine and esketamine lack a therapeutic delay and do not increase risk for suicidal thoughts and behaviors in adolescents and young-adults. Esketamine gained FDA approval in March of 2019.
Comparable studies
Other narrative reviews on esketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Long-term safety of ketamine and esketamine in treatment of depression | 2022 | Review | |
| Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms. | 2024 | Review | |
| Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review. Patients with depression | 2024 | Narrative review | |
| The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease | 2022 | Review |